Overview

B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.

Status:
Completed

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

The hypothesis is that a subgroup of patients with Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME) have a chronically activated immune system and may benefit from B-lymphocyte treatment using the monoclonal anti-CD20 antibody rituximab with induction and maintenance treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Haukeland University Hospital

Collaborators:

MEandYou Foundation
Norwegian Department of Health and Social Affairs
Oslo University Hospital
St. Olavs Hospital
Sykehuset Telemark
The Kavli Foundation
The Norwegian ME association
The Research Council of Norway
Trondheim University Hospital
University Hospital of North Norway

Treatments:

Rituximab